CMLF — Stock Film
STOCK FILMSCENE 1/9CMLF · $11.60
Stock Expert AI presents
CMLF
CM Life Sciences, Inc
~3 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
CM Life Sciences, Inc. A quick introduction.

On the stock market since 2020, it operates in the world of money and finance. Now — the numbers.

on the stock market since 2020
$0 market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.

WHERE DOES THE MONEY COME FROM?
49%Diagnostic Test
Diagnostic Test 49%Diagnostic Test, Third Party Insurance 41%Diagnostic Test, Institutional Customers 8%Product and Service, Other 1%Diagnostic Test, Self Pay <1%
49% of all revenue comes from a single line: Diagnostic Test.

The biggest line carries real weight, but it doesn’t decide everything on its own.

In the vault right now:
$0
DEBT: $60.5M
At this pace, that money lasts about 8.1 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 55% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $427.5M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 3 buys and 1 sell. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small scale, thin loss

A loss of $21.0M against $427.5M in annual sales.

2
THE RISKS · 2/2
The stock has lost its spark

Since the drop from its peak, buyer appetite hasn’t come back.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, CMLF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: CMLF is a high-risk stock — not yet profitable, and its future rides on its product catching on.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film